Hoth Therapeutics IncHOTH announced Phase 1b trial data for BioLexa in adult patients with mild-to-moderate atopic dermatitis.
Using the SCORAD as a clinical tool for assessing the severity of atopic dermatitis (scale) and EASI score, a tool used to measure the extent (area) and severity of atopic eczema, all patients showed improvement during the study compared to the day one score.
Using the EASI scale, 100% of patients showed clinically-relevant improvement >50% compared to Day 1 during the entire 28-day study treatment period.
Using SCORAD, 60% of patients showed overall clinically relevant improvement (>35% improvement) during the study compared to the Day 1 score.
42% of patients maintained improvement from day 14 to day 28, supporting the long-term effect of BioLexa.
A clinically relevant reduction in the total body surface area affected by atopic dermatitis was observed in 71% of patients treated with BioLexa. The total reduction of these patients ranged from 37.5% to 71.4%.
BioLexa was well tolerated, with no serious adverse events and no drug-related treatment-emergent adverse events observed.
Price Action: HOTH shares are up 25.2% at $7.13 on the last check Monday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
